Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development

The aim of the present work was to develop immediate release dosage form of the solid dispersion of glimperide (GLIM) for potential enhancement in the bioavailability. The solid dispersions of GLIM were prepared with PEG6000, PVP K30 and Poloxamer 188, in 1:1, 1:3 and 1:5 %w/w ratio by using solvent...

Full description

Bibliographic Details
Main Authors: Kamla Pathak, Suchitra Kaushik
Format: Article
Language:English
Published: Mazandaran University of Medical Sciences 2017-12-01
Series:Pharmaceutical and Biomedical Research
Subjects:
Online Access:http://pbr.mazums.ac.ir/article-1-181-en.pdf
id doaj-f9e7eebe730c4534af007f74c5ef2811
record_format Article
spelling doaj-f9e7eebe730c4534af007f74c5ef28112020-11-25T00:55:11ZengMazandaran University of Medical SciencesPharmaceutical and Biomedical Research2423-44942423-44942017-12-013411310.18502/pbr.v3i4.84Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form developmentKamla Pathak0Suchitra Kaushik1Pharmacy College Saifai, Uttar Pradesh University of Medical Sciences, Etawah, 206130, INDIAPharmacy College Saifai, Uttar Pradesh University of Medical Sciences, Etawah, 206130, INDIAThe aim of the present work was to develop immediate release dosage form of the solid dispersion of glimperide (GLIM) for potential enhancement in the bioavailability. The solid dispersions of GLIM were prepared with PEG6000, PVP K30 and Poloxamer 188, in 1:1, 1:3 and 1:5 %w/w ratio by using solvent wetting and solvent melt method. The in vitro dissolution parameters (%DE10min, %DE30min, %DE60min, T50% and DP30) were used to select the optimized solid dispersion that was characterized by IR, PXRD, DSC and SEM. The optimized solid dispersion of GLIM (GSDSM3) was used as drug component for immediate release (IR) tablets that were evaluated for physical and pharmacopoeial parameters. The in vitro drug release studies identified G4 as the optimized tablet with a cumulative drug release (CDR) of 99.34% in 30 min in phosphate buffer, pH 7.4. The CDR was higher than the marketed tablet (91.15%, Amaryl®, Sanofiaventis), However, the f1 and f2 were 10.6 and 52 respectively, which confirmed similarity of the dissolution profile(s). Accelerated stability studies confirmed stability up to 6 months at 40°C/75% condition in the HDPE bottle pack.http://pbr.mazums.ac.ir/article-1-181-en.pdfGlimperidesolid dispersionsolvent wetting methodsolvent melt methodimmediate release tablet
collection DOAJ
language English
format Article
sources DOAJ
author Kamla Pathak
Suchitra Kaushik
spellingShingle Kamla Pathak
Suchitra Kaushik
Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development
Pharmaceutical and Biomedical Research
Glimperide
solid dispersion
solvent wetting method
solvent melt method
immediate release tablet
author_facet Kamla Pathak
Suchitra Kaushik
author_sort Kamla Pathak
title Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development
title_short Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development
title_full Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development
title_fullStr Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development
title_full_unstemmed Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development
title_sort solubility enhancement of glimperide: development of solid dispersion by solvent melt method, characterization and dosage form development
publisher Mazandaran University of Medical Sciences
series Pharmaceutical and Biomedical Research
issn 2423-4494
2423-4494
publishDate 2017-12-01
description The aim of the present work was to develop immediate release dosage form of the solid dispersion of glimperide (GLIM) for potential enhancement in the bioavailability. The solid dispersions of GLIM were prepared with PEG6000, PVP K30 and Poloxamer 188, in 1:1, 1:3 and 1:5 %w/w ratio by using solvent wetting and solvent melt method. The in vitro dissolution parameters (%DE10min, %DE30min, %DE60min, T50% and DP30) were used to select the optimized solid dispersion that was characterized by IR, PXRD, DSC and SEM. The optimized solid dispersion of GLIM (GSDSM3) was used as drug component for immediate release (IR) tablets that were evaluated for physical and pharmacopoeial parameters. The in vitro drug release studies identified G4 as the optimized tablet with a cumulative drug release (CDR) of 99.34% in 30 min in phosphate buffer, pH 7.4. The CDR was higher than the marketed tablet (91.15%, Amaryl®, Sanofiaventis), However, the f1 and f2 were 10.6 and 52 respectively, which confirmed similarity of the dissolution profile(s). Accelerated stability studies confirmed stability up to 6 months at 40°C/75% condition in the HDPE bottle pack.
topic Glimperide
solid dispersion
solvent wetting method
solvent melt method
immediate release tablet
url http://pbr.mazums.ac.ir/article-1-181-en.pdf
work_keys_str_mv AT kamlapathak solubilityenhancementofglimperidedevelopmentofsoliddispersionbysolventmeltmethodcharacterizationanddosageformdevelopment
AT suchitrakaushik solubilityenhancementofglimperidedevelopmentofsoliddispersionbysolventmeltmethodcharacterizationanddosageformdevelopment
_version_ 1725231547788820480